|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HIPK2 |
Gene summary for HIPK2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HIPK2 | Gene ID | 28996 |
| Gene name | homeodomain interacting protein kinase 2 | |
| Gene Alias | PRO0593 | |
| Cytomap | 7q34 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9H2X6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 28996 | HIPK2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.64e-02 | 4.24e-01 | -0.0811 |
| 28996 | HIPK2 | HTA11_78_2000001011 | Human | Colorectum | AD | 4.10e-04 | 5.89e-01 | -0.1088 |
| 28996 | HIPK2 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.08e-07 | 5.58e-01 | -0.1954 |
| 28996 | HIPK2 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.85e-03 | 3.64e-01 | -0.1464 |
| 28996 | HIPK2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.51e-03 | 5.17e-01 | -0.059 |
| 28996 | HIPK2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 9.47e-03 | 3.65e-01 | 0.0674 |
| 28996 | HIPK2 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 6.35e-03 | 9.82e-01 | 0.3487 |
| 28996 | HIPK2 | A015-C-203 | Human | Colorectum | FAP | 3.47e-13 | -1.54e-01 | -0.1294 |
| 28996 | HIPK2 | A015-C-204 | Human | Colorectum | FAP | 3.93e-02 | -1.25e-01 | -0.0228 |
| 28996 | HIPK2 | A002-C-201 | Human | Colorectum | FAP | 1.24e-05 | -4.85e-02 | 0.0324 |
| 28996 | HIPK2 | A002-C-203 | Human | Colorectum | FAP | 1.28e-02 | 2.25e-01 | 0.2786 |
| 28996 | HIPK2 | A001-C-108 | Human | Colorectum | FAP | 5.44e-07 | -9.74e-02 | -0.0272 |
| 28996 | HIPK2 | A002-C-021 | Human | Colorectum | FAP | 8.78e-03 | 2.96e-01 | 0.1171 |
| 28996 | HIPK2 | A002-C-205 | Human | Colorectum | FAP | 1.32e-12 | -1.10e-01 | -0.1236 |
| 28996 | HIPK2 | A015-C-006 | Human | Colorectum | FAP | 3.04e-10 | -2.84e-01 | -0.0994 |
| 28996 | HIPK2 | A015-C-106 | Human | Colorectum | FAP | 3.60e-04 | -3.09e-02 | -0.0511 |
| 28996 | HIPK2 | A002-C-114 | Human | Colorectum | FAP | 9.32e-11 | -6.80e-02 | -0.1561 |
| 28996 | HIPK2 | A015-C-104 | Human | Colorectum | FAP | 6.74e-16 | -6.46e-02 | -0.1899 |
| 28996 | HIPK2 | A001-C-014 | Human | Colorectum | FAP | 1.36e-04 | -1.06e-01 | 0.0135 |
| 28996 | HIPK2 | A002-C-016 | Human | Colorectum | FAP | 1.35e-09 | -1.54e-01 | 0.0521 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0042176 | Colorectum | AD | regulation of protein catabolic process | 160/3918 | 391/18723 | 1.06e-19 | 7.34e-17 | 160 |
| GO:1903362 | Colorectum | AD | regulation of cellular protein catabolic process | 109/3918 | 255/18723 | 2.14e-15 | 6.08e-13 | 109 |
| GO:0009895 | Colorectum | AD | negative regulation of catabolic process | 124/3918 | 320/18723 | 1.66e-13 | 3.35e-11 | 124 |
| GO:1903050 | Colorectum | AD | regulation of proteolysis involved in cellular protein catabolic process | 92/3918 | 221/18723 | 2.04e-12 | 3.19e-10 | 92 |
| GO:0031330 | Colorectum | AD | negative regulation of cellular catabolic process | 104/3918 | 262/18723 | 2.66e-12 | 3.96e-10 | 104 |
| GO:0097193 | Colorectum | AD | intrinsic apoptotic signaling pathway | 108/3918 | 288/18723 | 6.25e-11 | 6.41e-09 | 108 |
| GO:0051098 | Colorectum | AD | regulation of binding | 126/3918 | 363/18723 | 6.01e-10 | 4.88e-08 | 126 |
| GO:0042177 | Colorectum | AD | negative regulation of protein catabolic process | 55/3918 | 121/18723 | 1.19e-09 | 8.85e-08 | 55 |
| GO:2000058 | Colorectum | AD | regulation of ubiquitin-dependent protein catabolic process | 68/3918 | 164/18723 | 1.82e-09 | 1.31e-07 | 68 |
| GO:1903363 | Colorectum | AD | negative regulation of cellular protein catabolic process | 39/3918 | 75/18723 | 2.69e-09 | 1.87e-07 | 39 |
| GO:0051099 | Colorectum | AD | positive regulation of binding | 66/3918 | 173/18723 | 1.47e-07 | 6.64e-06 | 66 |
| GO:1903051 | Colorectum | AD | negative regulation of proteolysis involved in cellular protein catabolic process | 31/3918 | 64/18723 | 8.71e-07 | 2.98e-05 | 31 |
| GO:0034101 | Colorectum | AD | erythrocyte homeostasis | 51/3918 | 129/18723 | 1.07e-06 | 3.59e-05 | 51 |
| GO:0070997 | Colorectum | AD | neuron death | 114/3918 | 361/18723 | 1.13e-06 | 3.72e-05 | 114 |
| GO:0030099 | Colorectum | AD | myeloid cell differentiation | 119/3918 | 381/18723 | 1.24e-06 | 4.01e-05 | 119 |
| GO:0043393 | Colorectum | AD | regulation of protein binding | 68/3918 | 196/18723 | 5.17e-06 | 1.34e-04 | 68 |
| GO:0002262 | Colorectum | AD | myeloid cell homeostasis | 57/3918 | 157/18723 | 6.17e-06 | 1.56e-04 | 57 |
| GO:2000059 | Colorectum | AD | negative regulation of ubiquitin-dependent protein catabolic process | 24/3918 | 48/18723 | 7.38e-06 | 1.81e-04 | 24 |
| GO:0072331 | Colorectum | AD | signal transduction by p53 class mediator | 58/3918 | 163/18723 | 1.04e-05 | 2.40e-04 | 58 |
| GO:0048872 | Colorectum | AD | homeostasis of number of cells | 87/3918 | 272/18723 | 1.16e-05 | 2.61e-04 | 87 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04218 | Colorectum | AD | Cellular senescence | 53/2092 | 156/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 53 |
| hsa042181 | Colorectum | AD | Cellular senescence | 53/2092 | 156/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 53 |
| hsa042184 | Colorectum | FAP | Cellular senescence | 42/1404 | 156/8465 | 6.79e-04 | 4.63e-03 | 2.82e-03 | 42 |
| hsa042185 | Colorectum | FAP | Cellular senescence | 42/1404 | 156/8465 | 6.79e-04 | 4.63e-03 | 2.82e-03 | 42 |
| hsa0421816 | Endometrium | AEH | Cellular senescence | 37/1197 | 156/8465 | 8.49e-04 | 5.52e-03 | 4.04e-03 | 37 |
| hsa0421817 | Endometrium | AEH | Cellular senescence | 37/1197 | 156/8465 | 8.49e-04 | 5.52e-03 | 4.04e-03 | 37 |
| hsa0421825 | Endometrium | EEC | Cellular senescence | 40/1237 | 156/8465 | 1.89e-04 | 1.68e-03 | 1.25e-03 | 40 |
| hsa0421835 | Endometrium | EEC | Cellular senescence | 40/1237 | 156/8465 | 1.89e-04 | 1.68e-03 | 1.25e-03 | 40 |
| hsa0421829 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
| hsa0421838 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
| hsa042187 | Liver | Cirrhotic | Cellular senescence | 66/2530 | 156/8465 | 5.94e-04 | 3.60e-03 | 2.22e-03 | 66 |
| hsa0421812 | Liver | Cirrhotic | Cellular senescence | 66/2530 | 156/8465 | 5.94e-04 | 3.60e-03 | 2.22e-03 | 66 |
| hsa0421822 | Liver | HCC | Cellular senescence | 102/4020 | 156/8465 | 4.18e-06 | 3.59e-05 | 2.00e-05 | 102 |
| hsa0421832 | Liver | HCC | Cellular senescence | 102/4020 | 156/8465 | 4.18e-06 | 3.59e-05 | 2.00e-05 | 102 |
| hsa042188 | Lung | IAC | Cellular senescence | 40/1053 | 156/8465 | 4.44e-06 | 1.44e-04 | 9.59e-05 | 40 |
| hsa0421813 | Lung | IAC | Cellular senescence | 40/1053 | 156/8465 | 4.44e-06 | 1.44e-04 | 9.59e-05 | 40 |
| hsa0421823 | Lung | AIS | Cellular senescence | 35/961 | 156/8465 | 5.09e-05 | 7.85e-04 | 5.03e-04 | 35 |
| hsa0421833 | Lung | AIS | Cellular senescence | 35/961 | 156/8465 | 5.09e-05 | 7.85e-04 | 5.03e-04 | 35 |
| hsa0421820 | Oral cavity | OSCC | Cellular senescence | 112/3704 | 156/8465 | 8.04e-13 | 1.42e-11 | 7.21e-12 | 112 |
| hsa04218110 | Oral cavity | OSCC | Cellular senescence | 112/3704 | 156/8465 | 8.04e-13 | 1.42e-11 | 7.21e-12 | 112 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HIPK2 | SNV | Missense_Mutation | c.1945N>C | p.Asp649His | p.D649H | Q9H2X6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | |
| HIPK2 | SNV | Missense_Mutation | rs764542823 | c.350G>A | p.Arg117Gln | p.R117Q | Q9H2X6 | protein_coding | tolerated(0.2) | probably_damaging(0.978) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HIPK2 | SNV | Missense_Mutation | novel | c.2665N>G | p.Thr889Ala | p.T889A | Q9H2X6 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| HIPK2 | SNV | Missense_Mutation | c.1477N>A | p.Glu493Lys | p.E493K | Q9H2X6 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AR-A0TZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Doxorubicin | PD | |
| HIPK2 | SNV | Missense_Mutation | c.2108C>G | p.Ala703Gly | p.A703G | Q9H2X6 | protein_coding | deleterious(0) | benign(0.108) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD | |
| HIPK2 | SNV | Missense_Mutation | rs747709692 | c.280N>A | p.Val94Met | p.V94M | Q9H2X6 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-AR-A2LN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
| HIPK2 | SNV | Missense_Mutation | c.47N>G | p.Ser16Cys | p.S16C | Q9H2X6 | protein_coding | deleterious(0.02) | probably_damaging(0.993) | TCGA-B6-A3ZX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | |
| HIPK2 | SNV | Missense_Mutation | c.2220N>C | p.Glu740Asp | p.E740D | Q9H2X6 | protein_coding | tolerated(0.99) | benign(0.001) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| HIPK2 | SNV | Missense_Mutation | rs773782325 | c.140N>C | p.His47Pro | p.H47P | Q9H2X6 | protein_coding | tolerated(0.1) | possibly_damaging(0.71) | TCGA-C8-A1HO-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| HIPK2 | SNV | Missense_Mutation | rs773782325 | c.140N>C | p.His47Pro | p.H47P | Q9H2X6 | protein_coding | tolerated(0.1) | possibly_damaging(0.71) | TCGA-D8-A1JI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | 249565808 | ||
| 28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | TAMATINIB | R-406 | ||
| 28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | PI-103 | PI-103 | ||
| 28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | GSK-269962A | GSK-269962A | ||
| 28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | CENISERTIB | CENISERTIB | ||
| 28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | BAY-613606 | CHEMBL541400 | ||
| 28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | ILORASERTIB | ILORASERTIB | ||
| 28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | PF-562271 | PF-00562271 | ||
| 28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | PHA-767491 | CHEMBL225519 | ||
| 28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | SP-600125 | SP-600125 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |